Press Release Visus Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapies for indications in the front and back of the eye, today announced that Ben Bergo, co-founder and chief executive officer, will…
Visus Therapeutics to Present at 2023 JMP Securities Life Science Conference streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Brimochol PF, a once-daily eye drop under evaluation for the treatment of presbyopia, achieved primary and secondary endpoints in the pivotal phase 3 BRIO-I clinical trial, according to a press release from Visus Therapeutics.
Press Release Visus Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapies for indications in the front and back of the eye, today presented key topline data from the pivotal Phase 3 BRIO-I clinical trial….
SEATTLE & IRVINE, Calif. (BUSINESS WIRE) Visus Therapeutics Inc., a clinical stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapeutics for the front and back of the eye, today announced Jehan Tamboowalla joined the company as senior vice president of business development and mark.